Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Kazantseva, Marina G ^a   Highton, John ^a   Stamp, Lisa K ^a   Hessian, Paul A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CYTOCHROME P450 1A1; GAMMA INTERFERON RECEPTOR 1; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; AHR PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MONOCYTE; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SMOKING; SUBCUTANEOUS NODULE; SYNOVIUM; ADVERSE EFFECTS; AGONISTS; CELL CULTURE; DRUG EFFECTS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZO(A)PYRENE; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; DENDRITIC CELLS; FEMALE; HUMANS; IN VITRO TECHNIQUES; INFLAMMATION; INTERLEUKIN-17; MALE; MIDDLE AGED; RECEPTORS, ARYL HYDROCARBON; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SMOKING; SYNOVIAL MEMBRANE;

EID: 84866943867     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4046     Document Type: Article

References (46)

1. Masdottir B, Jónsson T, Manfredsdottir V, Víkingsson A, Brekkan A, Valdimarsson H. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatol 2000, 39:1202-1205.
2. Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M, Siqurdardittir SL, Valdmansson H, Vikingsson A. The effects of tobacco smoking and rheumatoid factor seropositivity on disease aticity and joint damage in early rheumatoid arthritis. Rheumatol 2006, 45:734-740.
3. Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatol 2008, 47:849-854.
4. Hyrich KL, Watson KD, Silman AJ, Symmons DP, . British Society for Rheumatology Biologics Register Predictors of response to anti-TNF alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatol 2006, 45:1558-1565. British Society for Rheumatology Biologics Register.
5. Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM. Anti-TNF alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. Journal of Clinical Rheumatology 2010, 16:15-18. 10.1097/RHU.0b013e3181ca4a2a, 20051749.
6. van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, Huizinga TW, van der Helm-van Mil AH. Prevalence of and predictive factors for sustained desease-modifying anti-rheumatic drug free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009, 60:2262-2271. 10.1002/art.24661, 19644846.
7. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000, 43:30-37. 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B, 10643697.
8. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010, 376:1094-1108. 10.1016/S0140-6736(10)60826-4, 20870100.
9. Moreno I, Valenzuela A, Garcia A, Yelamos J, Sanchez B, Hernanz W. Association of the shared epitope with radiological severity of rheumatoid arthritis. J Rheumatol 1996, 23:6-9.
10. Valenzuela A, Gonzalez-Escribano MF, Rodriguez R, Moreno I, Garcia A, Nunez-Roldan A. Association of HLA shared epitope with joint damage progression in rheumatoid arthritis. Hum Immunol 1999, 60:250-254. 10.1016/S0198-8859(98)00110-4, 10321962.
11. van der Helm-van Mil AH, Toes RE, Huizinga TW. Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1694-1696. 10.1136/ard.2009.123828, 20439292.
12. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekeran A, Davies LR, Li W, Tan A, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007, 357:1199-1209. 10.1056/NEJMoa073491, 2636867, 17804836.
13. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, Gregersen PK, Klareskog L, Rioux JD. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005, 77:1044-1060. 10.1086/498651, 1285162, 16380915.
14. Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993, 20:1830-1835.
15. Finckh A, Dehler S, Costenbader KH, Gabay C. Cigarette smoking and radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1066-1071. 10.1136/ard.2006.065060, 1954718, 17237117.
16. Harrison BJ, Silman AJ, Wiles NJ, Scott DG, Symmons DP. The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum 2001, 44:323-330. 10.1002/1529-0131(200102)44:2<323::AID-ANR49>3.0.CO;2-C, 11229462.
17. Masdottir B, Jonsson T, Manfredsdottir V, Vikingsson A, Brekkan A, Valdimarsson H. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatol 2000, 39:1202-1205.
18. Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatol 2008, 47:849-854.
19. Kitamura M, Kasai A. Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett 2007, 252:184-194. 10.1016/j.canlet.2006.11.015, 17189671.
20. Makrygiannakis D, Hermansson M, Ulfgren A-K, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskpg L, Catrina AI. Smoking increases peptigylarginine deiminase 2 enzyme expression in human lungs and increases cirullination in BAL cells. Ann Rheum Dis 2008, 67:1488-1492. 10.1136/ard.2007.075192, 18413445.
21. Mahdi H, Fisher BA, Kallberg H, Plant D, Malmstrom V, Ronnelid J, Charles P, Ding B, Alfredsson L, Padyukov L, Symmons DP, Venables PJ, Klareskog L, Lundberg K. Specific interaction between geneotype, smoking and autoimmuity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009, 41:1319-1324. 10.1038/ng.480, 19898480.
22. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstom V, Feldmann M, Venables PJ. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010, 233:34-54. 10.1111/j.0105-2896.2009.00850.x, 20192991.
23. Montes A, Dieguez-Gonzalez R, Perez-Pampin E, Calaza M, Mera-Varela A, Gomez-Reino JJ, Gonzalez A. Particular association of clinical and genetic features with autoimunity to citrullinated α-enolase in rheumatoid arthritis. Arthritis Rheum 2011, 63:654-661.
24. von Delwig A, Locke J, Robinson JH, Ng WF. Response of Th17 cells to citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:143-149.
25. Klareskog L, Ronnelid J, Lundberg K, Papyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Ann Rev Immunol 2008, 26:651-675.
26. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453:106-109. 10.1038/nature06881, 18362914.
27. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, Bresnihan B, Veale DJ, Fearon U. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 2009, 11:R113. 10.1186/ar2772, 2745795, 19627579.
28. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 2010, 12:R29. 10.1186/ar2936, 2875663, 20167120.
29. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?. Cytokine 2008, 41:84-91. 10.1016/j.cyto.2007.09.014, 18039580.
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
31. Stamp LK, Easson A, Pettersson L, Highton J, Hessian PA. Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J Rheumatol 2009, 36:2403-2408. 10.3899/jrheum.081304, 19797506.
32. Hock BD, Starling GC, Daniel PB, Hart DN. Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 1994, 83:573-581. 1415076, 7875738.
33. Coventry BJ, Lee PL, Gibbs D, Hart DN. Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 expression. Br J Cancer 2002, 86:546-551. 10.1038/sj.bjc.6600132, 2375292, 11870535.
34. Hock BD, Fearnley DB, Boyce A, McLellan AD, Sorg RV, Summers KL, Hart DN. Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens 1999, 53:320-334. 10.1034/j.1399-0039.1999.530402.x, 10323336.
35. Brauze D, Widerak M, Cwykiel J, Szyfter K, Baer-Dubowska W. The effect of aryl hydrocarbon receptor ligands on the expression of AhR, AhRR, ARNT, Hif1alpha, CYP1A1 and NQO1 genes in rat liver. Toxicol Lett 2006, 167:212-220. 10.1016/j.toxlet.2006.09.010, 17069994.
36. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122-1131. 10.1002/art.21749, 16572447.
37. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, Toes RE, Hulzinga TW, Klareskog L, Alfredsson L. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007, 80:867-875. 10.1086/516736, 1852748, 17436241.
38. Klareskog L, Gregersen PK, Huizinga TW. Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis 2010, 69:2062-2066. 10.1136/ard.2010.142109, 21097657.
39. Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62:383-391.
40. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, Askling J, Alfredsson L, Klareskog L. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011, 63:26-36. 10.1002/art.27758, 20862678.
41. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008, 21:102-116. 10.1021/tx7001965, 2572005, 18076143.
42. Simones T, Shepherd DM. Consequences of AhR activation in steady-state dendritic cells. Toxicol Sci 2010, 119:293-307. 3023567, 21097750.
43. Bankoti J, Rase B, Simones T, Shepherd DM. Functional and phenotypic effects of AhR activation in inflammatory dendritic cells. Toxicol Appl Pharmacol 2010, 246:18-28. 10.1016/j.taap.2010.03.013, 2885531, 20350561.
44. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA 2010, 107:19961-19966. 10.1073/pnas.1014465107, 2993339, 21041655.
45. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010, 185:3190-3198. 10.4049/jimmunol.0903670, 2952546, 20720200.
46. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wihelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, Stockinger B. Fate mapping of IL-17 producing T cells in inflammatory responses. Nat Immunol 2011, 12:255-263. 10.1038/ni.1993, 3040235, 21278737.